NovoCure Limited (NVCR) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 9 recommend buying, 5 recommend holding, and 1 recommend selling.
The analyst consensus price target for NVCR is $33.50, representing a +196.5% upside from the current price of $11.3. Price targets range from a low of $20.00 to a high of $47.00.
